Payment overview · 2025
General Payments
$258.82
11 reported records · 5 companies
Healthcare provider profile · identity verified
Tiffany Carlson, DO
Allopathic & Osteopathic Physicians|Family Medicine · CHICO, CA · NPI 1144581554
Verified facts
What the public records show
CMS Open Payments records show Tiffany Carlson, DO received $258.82 in general payments during 2025 across 11 reported records.
Amgen Inc. accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $76.68 | 29.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.39 | 26.4% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $66.40 | 25.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.65 | 9.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.70 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $258.82 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $66.40 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.59 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.59 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.66 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $33.09 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 479 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 395 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 215 | 63 |
| Lisinopril | Lisinopril | 187 | 62 |
| Losartan Potassium | Losartan Potassium | 150 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 43 |
| Omeprazole | Omeprazole | 121 | 37 |
| Metformin Hcl | Metformin Hcl | 119 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 41 |
| Simvastatin | Simvastatin | 101 | 31 |
| Alendronate Sodium | Alendronate Sodium | 98 | 31 |
| Gabapentin | Gabapentin | 86 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 16 |
| Montelukast Sodium | Montelukast Sodium | 72 | 24 |
| Atenolol | Atenolol | 61 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 17 |
| Estradiol | Estradiol | 55 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 19 |
| Eliquis | Apixaban | 53 | 13 |
| Synthroid | Levothyroxine Sodium | 46 | 16 |
| Trazodone Hcl | Trazodone Hcl | 45 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 44 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 14 |
| Famotidine | Famotidine | 42 | 15 |
| Sertraline Hcl | Sertraline Hcl | 39 | 13 |
| Carvedilol | Carvedilol | 37 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | 11 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 35 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 27 |
| Bupropion Xl | Bupropion Hcl | 33 | 12 |
| Prednisone | Prednisone | 32 | 25 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Valsartan | Valsartan | 32 | 11 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 29 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | 12 |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Furosemide | Furosemide | 23 | 11 |
| Ozempic | Semaglutide | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Spironolactone | Spironolactone | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 12 |
| Risperidone | Risperidone | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $258.82 · 11 records | Amgen Inc. | Dexcom G6 Transmitter, EVENITY, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, UBRELVY, VRAYLAR, Veozah, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error